Page last updated: 2024-10-24

celecoxib and Mucositis

celecoxib has been researched along with Mucositis in 1 studies

Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).

Research Excerpts

ExcerptRelevanceReference
"Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1."2.73Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Javle, MM1
Cao, S1
Durrani, FA1
Pendyala, L1
Lawrence, DD1
Smith, PF1
Creaven, PJ1
Noel, DC1
Iyer, RV1
Rustum, YM1

Trials

1 trial available for celecoxib and Mucositis

ArticleYear
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-01, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco

2007